US pharmaceutical giant Eli Lilly will unveil the full results of its trials of the drug 'donanemab' - which is the second shown to slow progression of dementia.

The results of the donanemab trial will be revealed at the Alzheimer’s Association International Conference in Amsterdam, and the drug could be licenced as safe in the UK in as little as a year to 18 months.

The NHS would then have to weigh up the cost effectiveness when it comes to who it can give the drug to.

Today's Mishal Husain speaks to Hilary Evans, Chief Executive of Alzheimer's Research UK and Co-Chair of UK Government Dementia Mission, and Professor Sir John Hardy, Professor of Neurodegenerative Disease at UCL - who advised the pharmaceutical company Eli Lilly during the development of donanemab.

Photo credit: Denis Balibouse, Reuters